Emerging drugs for schizophrenia

Ofer Agid, Shitij Kapur, Gary Remington

Research output: Contribution to journalLiterature reviewpeer-review

46 Citations (Scopus)


Background/objective: Schizophrenia is a chronic and disabling psychiatric disorder that requires lifelong medication. The past 15 years led to the introduction of a number of new drugs ('atypical') that have dramatically displaced the older drugs ('typical'), at least in Western markets. As the dust settles on this period and substantial data, as well as practical prescribing experience, are available, we examine what has been gained and what can be learned. Methods: Information available from various medical database resources: MEDLINE, EMBASE, Cochrane Database, ClinicalTrials.gov (a registry of federally and privately supported clinical trials) and schizophreniaforum.org - Drugs in Clinical Trials for Schizophrenia. Results.conclusion: It seems that the clinical benefits of the newer second-generation antipsychotics are modest, the greatest advantage being a reduction in motor side effects. The earlier hope that these agents have a primary effect on negative and cognitive symptoms is harder to sustain. Clozapine remains superior, even to other atypical antipsychotics, in treating refractory schizophrenia. On a mechanistic level, it seems that dopamine D-2 blockade is necessary and even sufficient for antipsychotic response (at least in some), though other receptors may contribute in ways that are not yet well understood.
Original languageEnglish
Pages (from-to)479 - 495
Number of pages17
JournalExpert Opinion on Emerging Drugs
Issue number3
Publication statusPublished - Sept 2008


Dive into the research topics of 'Emerging drugs for schizophrenia'. Together they form a unique fingerprint.

Cite this